Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 3:10 p.m. ET. A live webcast will be available via the Investors section of Kiniksa's website, with a replay posted within approximately 48 hours.

Key Figures

Conference date: March 2, 2026 Presentation time: 3:10 p.m. Eastern Time Replay availability: Within approximately 48 hours

3 metrics

Conference date March 2, 2026 TD Cowen 46th Annual Health Care Conference fireside chat

Presentation time 3:10 p.m. Eastern Time Scheduled start time for Kiniksa fireside chat

Replay availability Within approximately 48 hours Replay posted to company website after the event

Market Reality Check

Price: $42.76 Vol: Volume 1,200,034 is about...

high vol

$42.76 Last Close

Volume Volume 1,200,034 is about 2.3x the 20-day average of 521,919, indicating elevated trading activity ahead of this neutral conference update. high

Technical Price at $43.50 is trading above the 200-day MA of $36.00 despite the recent pullback.

Peers on Argus

KNSA fell 8.21% while peers showed mixed, mostly modest moves: SUPN up 4.61%, HC...

1 Up

KNSA fell 8.21% while peers showed mixed, mostly modest moves: SUPN up 4.61%, HCM up 1.89%, BHC up 0.33%, INDV down 0.42%, ALVO down 2.61%. Peer momentum data flags only BHC with a small move, supporting a stock-specific move rather than a sector-wide shift.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Earnings results	Positive	-8.2%	Strong 2025 ARCALYST growth and profitability with 2026 revenue outlook.
Feb 19	Earnings date notice	Neutral	+2.7%	Announcement of scheduled Q4 and full-year 2025 results call.
Jan 12	Corporate update	Positive	-3.6%	Unaudited 2025 ARCALYST revenue, growth metrics, and pipeline milestones.
Jan 7	Conference presentation	Neutral	-1.6%	J.P. Morgan Healthcare Conference appearance and webcast details.
Nov 12	Conference presentation	Neutral	-0.7%	Jefferies Global Healthcare Conference presentation and webcast access.

Pattern Detected

Recent history shows KNSA often trading lower after fundamentally positive updates and around conference appearances, indicating frequent negative price divergence from ostensibly constructive news.

Recent Company History

Over the last few months, Kiniksa reported strong ARCALYST growth and a move to profitability, with Q4 2025 net product revenue of $202.1M and full-year 2025 revenue of $677.6M, yet shares fell 8.21% after earnings on Feb 24. January’s corporate update also coincided with a 3.63% decline. Multiple conference participation announcements on Jan 7 and Nov 12 saw modest negative reactions. Today’s TD Cowen conference news fits a pattern of generally neutral events occurring against a backdrop of selling pressure following strong fundamentals.

Market Pulse Summary

This announcement adds another investor-relations touchpoint, with management presenting at TD Cowen...

Analysis

This announcement adds another investor-relations touchpoint, with management presenting at TD Cowen on March 2, 2026. It follows strong 2025 results, including ARCALYST revenue of $677.6M and net income of $59.0M, and comes after multiple recent conferences and corporate updates. Investors may focus on any incremental commentary around 2026 ARCALYST revenue expectations of $900–$920M and pipeline timing for KPL-387 and KPL-1161 as disclosed in earlier filings and releases.

AI-generated analysis. Not financial advice.

LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46^th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ^®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

FAQ

When will Kiniksa (KNSA) present at the TD Cowen 46th Annual Health Care Conference?

Kiniksa will present on March 2, 2026 at 3:10 p.m. ET. According to Kiniksa, the presentation is a fireside chat included in the TD Cowen 46th Annual Health Care Conference schedule.

How can investors watch Kiniksa's (KNSA) TD Cowen conference presentation live?

Investors can watch the presentation via a live webcast on Kiniksa's investor website. According to Kiniksa, the webcast will be accessible through the Investors section at www.kiniksa.com during the scheduled session.

Will Kiniksa (KNSA) provide a replay of its TD Cowen conference presentation?

Yes — a replay will be available on Kiniksa's website within approximately 48 hours after the event. According to Kiniksa, the replay will be posted in the Investors section for on-demand viewing.

What format will Kiniksa's (KNSA) presentation at TD Cowen take?

Kiniksa's management will participate in a fireside chat format at the conference. According to Kiniksa, the session is a moderated discussion featuring company management on March 2, 2026.

Where on the web will Kiniksa (KNSA) host the webcast and replay of the TD Cowen talk?

The live webcast and replay will be hosted on Kiniksa's investor relations website at www.kiniksa.com. According to Kiniksa, the content will be available through the Investors section of the site.